Washington Trust Advisors Inc. Has $33.27 Million Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

Washington Trust Advisors Inc. raised its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 0.1% in the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 140,408 shares of the medical research company’s stock after acquiring an additional 114 shares during the quarter. IQVIA makes up about 2.9% of Washington Trust Advisors Inc.’s portfolio, making the stock its 9th largest holding. Washington Trust Advisors Inc.’s holdings in IQVIA were worth $33,272,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in IQV. Versant Capital Management Inc boosted its stake in IQVIA by 733.3% during the second quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock worth $26,000 after acquiring an additional 110 shares in the last quarter. Opal Wealth Advisors LLC bought a new position in shares of IQVIA during the second quarter valued at about $27,000. Capital Performance Advisors LLP bought a new position in shares of IQVIA during the third quarter valued at about $27,000. Park Place Capital Corp bought a new position in shares of IQVIA during the third quarter valued at about $28,000. Finally, Itau Unibanco Holding S.A. purchased a new stake in IQVIA during the second quarter worth about $29,000. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at IQVIA

In other news, insider Eric Sherbet sold 1,300 shares of the business’s stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total value of $320,229.00. Following the completion of the transaction, the insider now directly owns 19,536 shares of the company’s stock, valued at $4,812,302.88. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Corporate insiders own 1.60% of the company’s stock.

IQVIA Stock Up 0.7 %

Shares of NYSE:IQV opened at $219.17 on Friday. The stock has a market cap of $39.78 billion, a P/E ratio of 28.76, a PEG ratio of 2.26 and a beta of 1.51. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76. IQVIA Holdings Inc. has a 52-week low of $190.20 and a 52-week high of $261.73. The business has a fifty day moving average of $231.00 and a two-hundred day moving average of $229.31.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the stock. JPMorgan Chase & Co. reduced their target price on shares of IQVIA from $279.00 to $240.00 and set an “overweight” rating for the company in a research note on Tuesday. BTIG Research dropped their target price on shares of IQVIA from $290.00 to $260.00 and set a “buy” rating for the company in a research report on Friday, November 1st. Royal Bank of Canada reiterated an “outperform” rating and set a $270.00 target price on shares of IQVIA in a research report on Friday, November 1st. StockNews.com lowered shares of IQVIA from a “buy” rating to a “hold” rating in a report on Friday. Finally, Redburn Atlantic started coverage on shares of IQVIA in a report on Monday, October 14th. They issued a “buy” rating and a $276.00 price objective for the company. Five equities research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $259.13.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.